Two cases are reported of recurrent fallopian tube carcinoma treated with CHIP (cis-dichloro-transdihydroxy-bis-isopropylamine platinum IV), a new cis-platinum analogue, resulting in one complete (though transient) and one good partial remission.
Introduction
Primary adenocarcinoma of the fallopian tube is a rare tumour of the female genital tract, with a reported incidence between 0.3% and 1.6% (Raju & Wiltshaw 1981) . The prognosis following surgery remains poor (Schiller & Silverberg 1971) , and due to the rarity of the tumour the efficacy of adjuvant radiotherapy and chemotherapy is not yet established.
Case reports
Case 1: A 59-year-old patient presented in April 1981 with postmenopausal bleeding and a pelvic mass. At laparotomy, her left fallopian tube was replaced by an infiltrating tumour which was adherent to the left ovary, the pouch of Douglas and the broad ligament. Tumour seedlings were also found in the peritoneal cavity and omentum but none in the liver. A clinical diagnosis of carcinoma of the fallopian tube, FIGO stage III, was made and a total hysterectomy with bilateral salpingo-oophorectomy was performed. Pathological examination of the specimen confirmed the diagnosis of primary adenocarcinoma of the fallopian tube.
The patient made an uneventful recovery, and was commenced on medroxyprogesterone acetate (Provera) and tamoxifen. She remained well until November 1982 when the pelvic mass recurred, and she was referred to Christie Hospital, Manchester. The presence and extent of the pelvic mass was confirmed by computerized axial tomography (CAT scan) ( Figure IA ) and a decision to treat the patient with the new cis-platinum analogue was made. CHIP 350 mg/M2 of surface area was administered intravenously every 4 weeks. The patient responded well after the first dose, and complete clinical remission was found 5 weeks after treatment commenced. The side effects encountered throughout treatment were severe nausea and vomiting in the first 24 hours immediately after drug administration and mild leukopenia of not less than 2 x 109/l, but there were no signs of peripheral neuropathy and the renal function remained normal throughout. The major toxicity was moderately severe thrombocytopenia of 28 x 109/l on day 14 of treatment which did not persist and recovered by day 21 to day 35, but it recurred with each course. Dose reduction was necessary because the nadir was lower with each course. After the third course the dose was reduced to 300 mg/M2, and the treatment interval was extended from 4 weeks to 6 weeks. 'Paper read to Section of Obstetrics & Gynaecology, 27 January 1984. Accepted 30 October 1984 2Present address: Prince of Wales Hospital, Shatin, New Territory, Hong Kong 3Present address: London Regional Cancer Centre, London, Ontario, Canada Case 2: A 38-year-old woman presented with a pelvic mass in May 1980. A carcinoma of the left fallopian tube with widespread peritoneal metastasis was found at laparotomy (FIGO stage III) and a total hysterectomy with bilateral salpingo-oophorectomy and omentectomy were performed. Postoperatively she was given oral treosulfan 1.25 g/day for six weeks and was referred to Christie Hospital. At that time there was no clinical evidence of disease and the patient was followed up with no further active treatment.
In 1981, a year after the initial referral, the patient presented with lower abdominal pain and a left pelvic mass, and a diagnosis of recurrent tubal carcinoma was made. The extent of the disease precluded radical surgery and the patient was treated with melphalan 10 mg daily for 5 days every 6 weeks. The patient left Britain and was lost to follow up until February 1983, when she was referred back with a recurrence in the vaginal vault while on oral Provera 100 mg daily. The recurrence continued to extend and by June 1983 the patient had developed severe abdominal discomfort and distension. A CAT scan was performed to assess the extent of the lesion (Figure 2A) and, after the baseline investigation, CHIP 300 mg/mr2 was commenced.
A good response was noted clinically and by CAT scan after 3 cycles of treatment ( Figure  2B ), but unfortunately the treatment had to be abandoned because of severe thrombocytopenia. Two weeks after the first course of treatment the platelet count fell to 6 x 109/l accompanied by bruising and purpura. Courses 2 and 3 were given at doses of 300 mg/M2 and 240 mg/M2 respectively but, despite these dose reductions, the platelet counts were <20 x 109/l at 2 weeks on both occasions with slow recovery over 6 to 7 weeks. Blood and platelet transfusion were necessary. Although there were no other untowards side effects, this marked and severe thrombocytopenia led to the cessation of CHIP after 3 cycles. The patient was subsequently treated with radiotherapy to eradicate the residual disease.
Discussion
The prognosis of primary carcinoma of the fallopian tube is generally poor, as the lack of specific symptoms and signs usually precludes diagnosis and treatment before dissemination takes place. Recurrence is common despite apparent adequate surgical removal, and postoperative radiotherapy does not prevent recurrence or prolong survival (Frankel 1956 , Hanton et al. 1966 , Roberts & Lifshitz 1982 , although it may perhaps increase the 5-year survival rate of patients with disease confined only to the fallopian tube (Amendola et al. 1983) .
Several authors employing single agents or combination chemotherapy have reported favourable responses to drugs such as adriamycin, melphalan, thiotepa and progestin (Guthrie & Cohen 1981 , Yoonessi 1979 , but there is no consensus on chemotherapy for this tumour because of its rarity. There are recent reports of the successful use of cis-platinum, either singly or with other agents. Deppe et al. (1980) described two patients with advanced adenocarcinoma of the fallopian tube treated with a combination of adriamycin, cis-platinum, cyclophosphamide and progestin who achieved a complete pathological remission. Raju & Wiltshaw (1981) reported one complete pathological remission and one partial remission in 2 of 4 patients treated with cis-platinum. The two non-responders in their study were given cis-platinum at a low dose (20 mg/M2) in combination with chlorambucil. Young et al. (1984) reported a patient who achieved a complete clinical response on a combination of cis-platinum, adriamycin and cyclophosphamide. Even though these studies have shown that cis-platinum is an effective agent in carcinoma of the fallopian tube, the drug has many toxic side effects. These include nephrotoxicity which is dose-related and cumulative, myelosuppression, ototoxicity, peripheral neuropathy, and troublesome nausea and vomiting.
The search for a new drug with similar antitumour activity comparable to cis-platinum, but lacking its serious side effects, has led to the synthesis of CHIP (cis-dichloro-transdihydroxy bis-isopropylamine platinum IV), an analogue of cis-platinum. Our preliminary data suggested that CHIP has less nephrotoxicity than cis-platinum (Thatcher et al. 1982) . In view of the favourable response of carcinoma of the fallopian tube to cis-platinum combinations, this new analogue CHIP was used in our 2 patients as part of a Phase I/II study of the drug (Bramwell et al. 1985) . CHIP was administered as a one-hour intravenous infusion with no preor post-hydration. It was repeated at 4-weekly intervals or after full recovery from toxicity. Four dose levels (180, 240, 300, 350 mg/m2) were investigated.
This Phase I/II study has shown that CHIP is highly active in ovarian cancer, particularly in patients who have received no prior chemotherapy (80% overall response, 60% complete clinical remission). As demonstrated in this report, the dose-limiting toxicity of CHIP was thrombocytopenia which was dose-related and cumulative. Although petechiae and minor bleeding were occasionally noted (as in Case 2), they were self-limiting and there was no serious haemorrhage. Gastrointestinal side effects like nausea and vomiting remained troublesome with CHIP, but were less severe and prolonged than after cis-platinum. Other side effects of cis-platinum were not encountered.
CHIP is a promising new platinum analogue. The favourable response demonstrated in our 2 patients should encourage wider collaborative trials of this drug in this rare tumour.
